<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Postepy Kardiol Interwencyjnej</journal-id><journal-id journal-id-type="iso-abbrev">Postepy Kardiol Interwencyjnej</journal-id><journal-id journal-id-type="publisher-id">PWKI</journal-id><journal-title-group><journal-title>Post&#x00119;py w Kardiologii Interwencyjnej = Advances in Interventional Cardiology</journal-title></journal-title-group><issn pub-type="ppub">1734-9338</issn><issn pub-type="epub">1897-4295</issn><publisher><publisher-name>Termedia Publishing House</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28344616</article-id><article-id pub-id-type="pmc">5364281</article-id><article-id pub-id-type="publisher-id">29540</article-id><article-id pub-id-type="doi">10.5114/aic.2017.66185</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>The impact of a single episode of remote ischemic preconditioning on myocardial injury after elective percutaneous coronary intervention</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Y&#x00131;lmaztepe</surname><given-names>Mustafa A.</given-names></name><xref ref-type="aff" rid="aff0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Taylan</surname><given-names>G&#x000f6;kay</given-names></name><xref ref-type="aff" rid="aff0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Aktoz</surname><given-names>Meryem</given-names></name><xref ref-type="aff" rid="aff0001">1</xref></contrib><contrib contrib-type="author"><name><surname>G&#x000fc;rlertop</surname><given-names>Hanefi Y.</given-names></name><xref ref-type="aff" rid="aff0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Aksoy</surname><given-names>Y&#x000fc;ksel</given-names></name><xref ref-type="aff" rid="aff0001">1</xref></contrib><contrib contrib-type="author"><name><surname>&#x000d6;z&#x000e7;elik</surname><given-names>Fatih</given-names></name><xref ref-type="aff" rid="aff0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Yalta</surname><given-names>Kenan</given-names></name><xref ref-type="aff" rid="aff0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Ekuklu</surname><given-names>Galip</given-names></name><xref ref-type="aff" rid="aff0002">2</xref></contrib></contrib-group><aff id="aff0001"><label>1</label>Department of Cardiology, School of Medicine, Trakya University, Edirne, Turkey</aff><aff id="aff0002"><label>2</label>Department of Public Health, School of Medicine, Trakya University, Edirne, Turkey</aff><author-notes><corresp id="cor1"><bold>Corresponding author:</bold> Mustafa Adem Yilmaztepe Assist. Prof., Department of Cardiology, School of Medicine, Trakya University, 22300 Edirne, Turkey. phone: +90 5335205712. e-mail: <email xlink:href="mayilmaztepe@yahoo.com">mayilmaztepe@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>13</volume><issue>1</issue><fpage>39</fpage><lpage>46</lpage><history><date date-type="received"><day>09</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>17</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2017 Termedia Sp. z o. o.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.</license-p></license></permissions><abstract><sec id="s1"><title>Introduction</title><p>Myocardial injury after percutaneous coronary intervention (PCI) occurs in approximately 30% of procedures, and is related to worse prognosis. Effects of remote ischemic preconditioning (RIPC) on reperfusion injury have been investigated before, yielding conflicting results.</p></sec><sec id="s2"><title>Aim</title><p>To assess the impact of a single episode of RIPC on myocardial injury after elective PCI.</p></sec><sec id="s3"><title>Material and methods</title><p>One hundred and four patients undergoing elective PCI, with normal baseline cardiac troponin-I (cTn-I) values, were randomized to two groups. Two patients were excluded due to data loss, and 102 patients were analyzed. Five minutes of ischemic preconditioning was delivered just before the intervention to the preconditioning group, by inflating the blood pressure cuff up to 200 mm Hg on the non-dominant arm. Postprocedural 16<sup>th</sup> hour cTn-I, &#x00394;cTn-I (difference between the 16<sup>th</sup> h and baseline cTn-I values) and the prevalence of type 4a myocardial infarction were compared between the two groups.</p></sec><sec id="s4"><title>Results</title><p>Median cTn-I values after the procedure were compared. 16<sup>th</sup> hour cTn-I was insignificantly lower in the preconditioning arm (0.026 &#x003bc;g/l vs. 0.045 &#x003bc;g/l, <italic>p</italic> = 0.186). The incidence of cTn-I elevation 5-fold above the upper reference limit (URL) (&#x0003e; 0.115 &#x003bc;g/l) was lower in the preconditioning group, but it was also not significant (21.6% vs. 11.8%, <italic>p</italic> = 0.184).</p></sec><sec id="s5"><title>Conclusions</title><p>A single episode of RIPC before elective PCI demonstrated less troponin elevation but failed to show a significant effect.</p></sec></abstract><kwd-group><kwd>percutaneous coronary intervention</kwd><kwd>remote ischemic preconditioning</kwd><kwd>myocardial injury</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Percutaneous coronary intervention (PCI) associated with myocardial enzyme elevation occurs in about 30% of interventions [<xref rid="cit0001" ref-type="bibr">1</xref>, <xref rid="cit0002" ref-type="bibr">2</xref>]. Although its clinical significance is controversial, it has been shown that even minor troponin elevations might be related to irreversible myocardial necrosis [<xref rid="cit0003" ref-type="bibr">3</xref>, <xref rid="cit0004" ref-type="bibr">4</xref>]. Myocardial injury after PCI can occur due to side branch occlusion, distal embolization, and ischemia/reperfusion injury [<xref rid="cit0002" ref-type="bibr">2</xref>, <xref rid="cit0005" ref-type="bibr">5</xref>]. Remote ischemic preconditioning (RIPC) has been demonstrated to prevent PCI-associated myocardial injury in ST segment elevation myocardial infarction (STEMI) and elective PCI cases [<xref rid="cit0006" ref-type="bibr">6</xref>]. Three cycles of ischemia (each lasting 5 min) preceding reperfusion were demonstrated to be beneficial in elective PCI, and this effect was still observed after 6 years, with lower major cardiovascular and cerebral events (MACCE) in the preconditioning arm [<xref rid="cit0007" ref-type="bibr">7</xref>, <xref rid="cit0008" ref-type="bibr">8</xref>]. However, since 3 cycles of ischemia and reperfusion are somewhat time-consuming, it is not practical to apply this technique, especially in ad-hoc PCI cases or in every patient before diagnostic angiography. There are limited data about the effects of a single episode of ischemic preconditioning. Ischemic preconditioning has been shown to be an all-or-nothing phenomenon [<xref rid="cit0009" ref-type="bibr">9</xref>, <xref rid="cit0010" ref-type="bibr">10</xref>], but it has also been shown that additional cycles of preconditioning could be more effective [<xref rid="cit0011" ref-type="bibr">11</xref>]. A recent study investigated the effect of one cycle of RIPC before elective PCI, and demonstrated its beneficial effects [<xref rid="cit0012" ref-type="bibr">12</xref>].</p></sec><sec id="sec2"><title>Aim</title><p>In this single-center, randomized, prospective study we planned to investigate the effect of a single episode of RIPC on troponin elevation after elective PCI.</p></sec><sec sec-type="material|methods" id="sec3"><title>Material and methods</title><p>Patients aged between 18 and 80 years of age, with a diagnosis of stable atherosclerotic heart disease primarily admitted to undergo elective coronary angiography between April 2015 and February 2016, were assessed for eligibility. The exclusion criteria were presence of 1) acute coronary syndrome, 2) left main disease, 3) baseline cardiac troponin-I (cTn-I) elevation (&#x0003e; 0.023 &#x003bc;g/l), 4) hemodynamic instability, 5) renal failure (a glomerular filtration rate (GFR) below or equal to a threshold value of 60 ml/min/1.73 m<sup>2</sup>), 6) glibenclamide or nicorandil use, 7) contraindication to cuff inflation in upper extremities (lymphoedema, fistula), 8) suspicion of pregnancy. Patients who did not give written informed consent were not enrolled in the study.</p><p>The study was approved by the Local Ethics Committee and was registered in the clinicaltrials.gov database. The study was conducted in accordance with the Declaration of Helsinki.</p><p>Three hundred and twenty-six patients undergoing coronary angiography were assessed for eligibility. Eighty-four patients were excluded because of high baseline cTn-I values or renal failure or for refusing to participate, and 138 patients were excluded after coronary angiography (did not receive PCI). Eligible patients were randomly allocated to groups. To prevent selection bias the randomization was performed by a third person who was blinded to the clinical information of the patients. A total of 104 patients were randomized. Two patients (one in each group) were excluded from the analysis, since post-PCI troponin values were missing. Data of 51 patients in the preconditioning group and 51 in the control group (total 102) were analyzed.</p><p>All patients were already using acetylsalicylic acid before coronary angiography. 600 mg of clopidogrel was given before PCI unless the patient was already using a P2Y12 inhibitor. A 70 IU/kg intravenous bolus of unfractionated heparin (UFH) was given to all patients after femoral sheath insertion and additional UFH was administered to maintain the activated clotting time &#x0003e; 250 s, if needed. All patients had blood pressure cuffs around their arm, but it was inflated to 200 mm Hg for 5 min in the preconditioning group only. The guiding catheter was advanced one minute after cuff deflation. Coronary intervention was performed according to the operator&#x02019;s discretion.</p><p>Systolic and diastolic blood pressure and heart rate during stent implantation, presence of chest pain and ST deviation on ECG monitor, lesion characteristics on angiography, predilatations, postdilatations, stent sizes, final angiographic results, and complications were all recorded. Target vessel lesions were classified according to the American Heart Association/American College of Cardiology lesion classification [<xref rid="cit0013" ref-type="bibr">13</xref>]. Pre- and post-procedural thrombolysis in myocardial infarction (TIMI) flow [<xref rid="cit0014" ref-type="bibr">14</xref>] was assessed by two independent operators, blinded to the troponin results and assigned study group of the patient.</p><p>To estimate the magnitude of the myocardium at risk, the Alberta Provincial Project for Outcome Assessment in Coronary Heart Diseases (APPROACH) [<xref rid="cit0015" ref-type="bibr">15</xref>] lesion score was used.</p><p>Sample size was determined according to the previous studies that showed a reduction in the prevalence of cTn-I elevation achieved by RIPC. While Zografos <italic>et al.</italic> [<xref rid="cit0012" ref-type="bibr">12</xref>] showed about 23% reduction, Hoole <italic>et al.</italic> [<xref rid="cit0007" ref-type="bibr">7</xref>] demonstrated 18% reduction. We assumed that a 20% percent reduction by RIPC would be clinically meaningful, and thus 88 patients would be enough to allow such a reduction to be significant (&#x003b1; = 0.05; &#x003b2; = 0.2; statistical power = 80%).</p><sec id="sec3.1"><title>Laboratory measurement</title><p>Following a 12-hour fasting period, blood samples were collected before the procedure. cTn-I was measured before and at the 16<sup>th</sup> h after the intervention. cTn-I was analyzed from lithium-heparinised plasma with the AQT90 FLEX TnI immunoassay (Radiometer Medical ApS, Denmark). The limit of detection has been determined to be 0.0095 &#x003bc;g/l. The reportable range of the assay is 0.010&#x02013;50 &#x003bc;g/l. The upper 99<sup>th</sup> percentile upper reference limit (URL) has been determined to be &#x02264; 0.023 &#x003bc;g/l. Values below 0.01 &#x003bc;g/l were accepted as 0.</p></sec><sec id="sec3.2"><title>Statistical analysis</title><p>Statistical analysis was performed using IBM SPSS (IBM SPSS Statistics for Windows, Version 20.0 Armonk, NY, IBM Corp). Continuous variables (heart rate, systolic and diastolic blood pressure, etc.) were summarized as mean, standard deviation, minimum, maximum, and median, and compared using Student&#x02019;s <italic>t</italic> test or the Mann-Whitney <italic>U</italic> test when appropriate. Categorical data (target vessel, lesion type etc.) were expressed as numbers and percentages and compared using the &#x003c7;<sup>2</sup> test. A value of <italic>p</italic> &#x0003c; 0.05 was accepted as significant.</p></sec></sec><sec sec-type="results" id="sec4"><title>Results</title><p>One hundred four patients were randomized. Two patients (one from each group) were excluded from the analysis because of missing post-PCI blood samples. The PCI was successfully performed in all randomized patients. With the exception of 2 patients in the preconditioning group all patients underwent stent implantation; in-stent balloon angioplasty was preferred in these 2 patients.</p><sec id="sec4.1"><title>Baseline demographic and clinical characteristics</title><p>There were no significant differences between the two groups with regards to sex, age and risk factors of atherosclerosis, renal functions, and medications used. Six patients in the control group and 4 patients in the preconditioning group had exercise-induced angina in the last 24 h but none of the patients had angina in the last 12 h (<italic>p</italic> = 0.505) (<xref ref-type="table" rid="t0001">Table I</xref>).</p><table-wrap id="t0001" position="float"><label>Table I</label><caption><p>Demographic and clinical data of patients</p></caption><table frame="void" rules="rows"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Controls (<italic>n</italic> = 51)</th><th align="center" rowspan="1" colspan="1">Preconditioning (<italic>n</italic> = 51)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">Demographics:</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Age [years]</td><td align="center" rowspan="1" colspan="1">60.9 &#x000b1;10.8</td><td align="center" rowspan="1" colspan="1">57.7 &#x000b1;8.9</td><td align="center" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female/male, <italic>n</italic>/<italic>n</italic>
</td><td align="center" rowspan="1" colspan="1">13/38</td><td align="center" rowspan="1" colspan="1">13/38</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" colspan="4" rowspan="1">Risk factors:</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hypertension, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">42 (82.4)</td><td align="center" rowspan="1" colspan="1">47 (92.2)</td><td align="center" rowspan="1" colspan="1">0.138</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hyperlipidemia, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">44 (86.3)</td><td align="center" rowspan="1" colspan="1">44 (86.3)</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Family history, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">7 (13.7)</td><td align="center" rowspan="1" colspan="1">15 (29.4)</td><td align="center" rowspan="1" colspan="1">0.054</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Smokers, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">35 (68.6)</td><td align="center" rowspan="1" colspan="1">33 (64.7)</td><td align="center" rowspan="1" colspan="1">0.674</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Diabetes mellitus, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">15 (29.4)</td><td align="center" rowspan="1" colspan="1">16 (31.4)</td><td align="center" rowspan="1" colspan="1">0.830</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;BMI [kg/m<sup>2</sup>]</td><td align="center" rowspan="1" colspan="1">28.55 &#x000b1;4.82</td><td align="center" rowspan="1" colspan="1">29.07 &#x000b1;4.24</td><td align="center" rowspan="1" colspan="1">0.563</td></tr><tr><td align="left" colspan="4" rowspan="1">Clinical features:</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;LVEF (%)</td><td align="center" rowspan="1" colspan="1">58.68 &#x000b1;8.94</td><td align="center" rowspan="1" colspan="1">58.11 &#x000b1;7.54</td><td align="center" rowspan="1" colspan="1">0.729</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;GFR [ml/min/1.73 m<sup>2</sup>]</td><td align="center" rowspan="1" colspan="1">91.3 &#x000b1;19.1</td><td align="center" rowspan="1" colspan="1">89.5 &#x000b1;16.7</td><td align="center" rowspan="1" colspan="1">0.613</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;CCS 2/3, <italic>n</italic>/<italic>n</italic>
</td><td align="center" rowspan="1" colspan="1">18/33</td><td align="center" rowspan="1" colspan="1">30/21</td><td align="center" rowspan="1" colspan="1">0.017</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Previous MI, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">10 (19.6)</td><td align="center" rowspan="1" colspan="1">11 (21.6)</td><td align="center" rowspan="1" colspan="1">0.807</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Previous CABG-O, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">3 (5.9)</td><td align="center" rowspan="1" colspan="1">3 (5.9)</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Last 24-hour angina, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">6 (11.8)</td><td align="center" rowspan="1" colspan="1">4 (7.8)</td><td align="center" rowspan="1" colspan="1">0.505</td></tr><tr><td align="left" colspan="4" rowspan="1">Medications, <italic>n</italic> (%):</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x003b2;-blockers</td><td align="center" rowspan="1" colspan="1">48 (94.1)</td><td align="center" rowspan="1" colspan="1">48 (94.1)</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;ACEI/ARB</td><td align="center" rowspan="1" colspan="1">39 (76.5)</td><td align="center" rowspan="1" colspan="1">40 (78.4)</td><td align="center" rowspan="1" colspan="1">0.813</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Ca-channel blocker</td><td align="center" rowspan="1" colspan="1">9 (17.6)</td><td align="center" rowspan="1" colspan="1">10 (19.6)</td><td align="center" rowspan="1" colspan="1">0.799</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Statins</td><td align="center" rowspan="1" colspan="1">37 (72.5)</td><td align="center" rowspan="1" colspan="1">36 (70.6)</td><td align="center" rowspan="1" colspan="1">0.826</td></tr></tbody></table><table-wrap-foot><fn><p>ACEI &#x02013; angiotensin-converting enzyme inhibitor, ARB &#x02013; angiotensin II receptor blocker, BMI &#x02013; body mass index, CCS &#x02013; Canadian Cardiology Society, CABG-O &#x02013; coronary artery bypass graft operation, GFR &#x02013; glomerular filtration rate, LVEF &#x02013; left ventricular ejection fraction, MI &#x02013; myocardial infarction.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec4.2"><title>Procedural characteristics</title><p>There were no procedural differences between the two groups. The procedural blood pressure values (systolic and diastolic) and heart rates were similar in the two groups. The two groups also did not differ significantly with regards to predilatation times and numbers, postdilatation times and numbers, total dilatation time and number, or stent size and stent numbers. Lesion type, bifurcation procedure, and APPROACH score were also similar between the two groups (<xref ref-type="table" rid="t0002">Table II</xref>).</p><table-wrap id="t0002" position="float"><label>Table II</label><caption><p>Angiographic and procedural data of patients</p></caption><table frame="void" rules="rows"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Controls (<italic>n</italic> = 51)</th><th align="center" rowspan="1" colspan="1">Preconditioning (<italic>n</italic> = 51)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">Angiographic parameters:</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Target vessel, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.400</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;LAD</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;LCx</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;RCA</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Combined/other</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Lesion AHA/ACC, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.746</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Type A</td><td align="center" rowspan="1" colspan="1">8 (15.7)</td><td align="center" rowspan="1" colspan="1">11 (21.6)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Type B</td><td align="center" rowspan="1" colspan="1">25 (49)</td><td align="center" rowspan="1" colspan="1">23 (45.1)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Type C</td><td align="center" rowspan="1" colspan="1">18 (35.3)</td><td align="center" rowspan="1" colspan="1">17 (33.3)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;APPROACH score (%)</td><td align="center" rowspan="1" colspan="1">28.15 &#x000b1;13.26</td><td align="center" rowspan="1" colspan="1">25.65 &#x000b1;11.99</td><td align="center" rowspan="1" colspan="1">0.321</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Stenosis severity (%)</td><td align="center" rowspan="1" colspan="1">81.7 &#x000b1;9.6</td><td align="center" rowspan="1" colspan="1">81.5 &#x000b1;91.3</td><td align="center" rowspan="1" colspan="1">0.891</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265; 2 mm side branch, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">13 (25.5)</td><td align="center" rowspan="1" colspan="1">8 (15.7)</td><td align="center" rowspan="1" colspan="1">0.221</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;TIMI flow 0-2, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">7 (13.7)</td><td align="center" rowspan="1" colspan="1">3 (5.8)</td><td align="center" rowspan="1" colspan="1">0.183</td></tr><tr><td align="left" colspan="4" rowspan="1">Procedural data:</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Heart rate [beats/min]</td><td align="center" rowspan="1" colspan="1">77.45 &#x000b1;10.89</td><td align="center" rowspan="1" colspan="1">74.19 &#x000b1;9.43</td><td align="center" rowspan="1" colspan="1">0.110</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Systolic blood pressure [mm Hg]</td><td align="center" rowspan="1" colspan="1">138.37 &#x000b1;15.03</td><td align="center" rowspan="1" colspan="1">140.7 &#x000b1;18.85</td><td align="center" rowspan="1" colspan="1">0.491</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Diastolic blood pressure [mm Hg]</td><td align="center" rowspan="1" colspan="1">77.54 &#x000b1;7.41</td><td align="center" rowspan="1" colspan="1">75.96 &#x000b1;8.11</td><td align="center" rowspan="1" colspan="1">0.305</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Procedural angina, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">26 (51)</td><td align="center" rowspan="1" colspan="1">24 (47.1)</td><td align="center" rowspan="1" colspan="1">0.692</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Procedural ST deviation, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">16 (31.4)</td><td align="center" rowspan="1" colspan="1">13 (25.5)</td><td align="center" rowspan="1" colspan="1">0.510</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Bifurcation procedure, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">3 (5.8)</td><td align="center" rowspan="1" colspan="1">4 (7.8)</td><td align="center" rowspan="1" colspan="1">0.603</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;DES/BMS/Balloon, <italic>n</italic>/<italic>n</italic>/<italic>n</italic>
</td><td align="center" rowspan="1" colspan="1">46/5/0</td><td align="center" rowspan="1" colspan="1">48/1/2</td><td align="center" rowspan="1" colspan="1">0.095</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Stent length [mm]</td><td align="center" rowspan="1" colspan="1">27.17 &#x000b1;13.79</td><td align="center" rowspan="1" colspan="1">26.12 &#x000b1;11.88</td><td align="center" rowspan="1" colspan="1">0.684</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Stent number</td><td align="center" rowspan="1" colspan="1">1.31 &#x000b1;0.55</td><td align="center" rowspan="1" colspan="1">1.17 &#x000b1;0.52</td><td align="center" rowspan="1" colspan="1">0.196</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Stent diameter [mm]</td><td align="center" rowspan="1" colspan="1">2.85 &#x000b1;0.4</td><td align="center" rowspan="1" colspan="1">2.83 &#x000b1;0.39</td><td align="center" rowspan="1" colspan="1">0.841</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Total dilatation time [s]</td><td align="center" rowspan="1" colspan="1">74.25 &#x000b1;55.5</td><td align="center" rowspan="1" colspan="1">81.4 &#x000b1;44.6</td><td align="center" rowspan="1" colspan="1">0.476</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Predilatation, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">20 (39.2)</td><td align="center" rowspan="1" colspan="1">22 (43.1)</td><td align="center" rowspan="1" colspan="1">0.687</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Postdilatation, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">31 (60.8)</td><td align="center" rowspan="1" colspan="1">33 (64.7)</td><td align="center" rowspan="1" colspan="1">0.682</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Predilatation time [s]</td><td align="center" rowspan="1" colspan="1">33.57 &#x000b1;34.17</td><td align="center" rowspan="1" colspan="1">25.35 &#x000b1;19.76</td><td align="center" rowspan="1" colspan="1">0.355</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Postdilatation time [s]</td><td align="center" rowspan="1" colspan="1">43.61 &#x000b1;27.78</td><td align="center" rowspan="1" colspan="1">48.47 &#x000b1;25.52</td><td align="center" rowspan="1" colspan="1">0.458</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Total dilatation number</td><td align="center" rowspan="1" colspan="1">3.6 &#x000b1;2.8</td><td align="center" rowspan="1" colspan="1">3.7 &#x000b1;2.3</td><td align="center" rowspan="1" colspan="1">0.845</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Cuff deflation to stent implantation time [s]</td><td align="center" rowspan="1" colspan="1">&#x02013;</td><td align="center" rowspan="1" colspan="1">432.9 &#x000b1;221.1</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Post-PCI results:</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;TIMI flow 2/3, <italic>n</italic>/<italic>n</italic>
</td><td align="center" rowspan="1" colspan="1">0/51</td><td align="center" rowspan="1" colspan="1">2/49</td><td align="center" rowspan="1" colspan="1">0.153</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Dissection</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Death</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;TIMI flow 0-2 at side branch</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn><p>BMS &#x02013; bare metal stent, DES &#x02013; drug-eluting stent, LAD &#x02013; left anterior descending artery, LCx &#x02013; left circumflex artery, RCA &#x02013; right coronary artery, PCI &#x02013; percutaneous coronary intervention, TIMI &#x02013; thrombolysis in myocardial infarction.</p></fn></table-wrap-foot></table-wrap><p>Baseline and post-PCI 16<sup>th</sup> h cTn-I values are shown in <xref ref-type="fig" rid="f0001">Figure 1</xref>. 16<sup>th</sup> h cTn-I values were lower in the preconditioning group, but the difference was not significant (0.032 &#x003bc;g/l vs. 0.057 &#x003bc;g/l, <italic>p</italic> = 0.186). &#x00394;cTn-I (difference between the 16<sup>th</sup> h and baseline cTn-I values) was also compared. &#x00394;cTn-I was lower in the preconditioning group, but the difference was not significant (0.045 &#x003bc;g/l (interquartile range: 0.013&#x02013;0.099) vs. 0.026 &#x003bc;g/l (interquartile range: 0.011&#x02013;0.057), <italic>p</italic> &#x0003c; 0.096).</p><fig id="f0001" position="float"><label>Figure 1</label><caption><p>Median (interquartile range) cardiac troponin-I (cTn-I) values at baseline (<bold>A</bold>) and 16 h after PCI (<bold>B</bold>). The 25<sup>th</sup> and 75<sup>th</sup> percentiles are indicated by the shaded box. The line within the box represents the median value</p></caption><graphic xlink:href="PWKI-13-29540-g001"/></fig><p>The prevalence of patients with cTn-I above the upper reference limit (URL) (&#x0003e; 0.023 &#x003bc;g/l) and cTn-I elevation 5-fold above the URL (&#x0003e; 0.115 &#x003bc;g/l) was lower in the preconditioning group, but the differences were also not significant (cTn-I &#x0003e; URL; 64.7% vs. 72.5%, <italic>p</italic> = 0.160, cTn-I &#x0003e; 5 &#x000d7; URL; 21.6% vs. 11.8%, <italic>p</italic> = 0.184) (<xref ref-type="fig" rid="f0002">Figure 2</xref>).</p><fig id="f0002" position="float"><label>Figure 2</label><caption><p>Prevalence of cardiac troponin-I (cTn-I) above upper reference limit (URL) and above 5 &#x000d7; URL</p></caption><graphic xlink:href="PWKI-13-29540-g002"/></fig></sec></sec><sec sec-type="discussion" id="sec5"><title>Discussion</title><p>The present study demonstrated that single cycle RIPC just before elective PCI may have favorable effects on reducing post-PCI troponin elevation, but failed to show a statistically significant difference.</p><p>The rate of PCI related myocardial injury varies according to the biomarker and cut-off value chosen. In a recently published article mild to moderate periprocedural myocardial injury was detected in 49.8% of the patients and severe myocardial injury was detected in 12.2% of the patients [<xref rid="cit0016" ref-type="bibr">16</xref>]. Some authors argue that high-sensitivity troponin measurement after PCI can be over-diagnostic; however, it has also been shown that patients with higher troponin levels have worse prognosis [<xref rid="cit0004" ref-type="bibr">4</xref>, <xref rid="cit0017" ref-type="bibr">17</xref>]. Although there is controversy about the cut-off values for troponin and creatinine kinase (CK)-MB in the determination of PCI-related myocardial infarction [<xref rid="cit0018" ref-type="bibr">18</xref>], the third Universal Definition of Myocardial Infarction Guideline [<xref rid="cit0019" ref-type="bibr">19</xref>] recommended troponin measurement after PCI and defined myocardial infarction after PCI (type 4a MI) as a 5-fold increase of troponin with clinical or electrocardiographic evidence. Solely troponin elevation above the URL, or values 5-fold above the URL without clinical or ECG findings, is defined as myocardial injury. Myocardial injury after PCI is due to microembolization of small debris, side branch occlusion, or ischemia/reperfusion injury.</p><p>Remote ischemic preconditioning has been investigated in several studies in an effort to obviate ischemia/reperfusion injury of the myocardium. Ischemic preconditioning was first demonstrated by Murry <italic>et al</italic>., by applying four cycles of intermittent nonlethal ischemia and reperfusion to the left anterior descending artery of a canine heart, which resulted in a 75% reduction in infarct size in the preconditioning group [<xref rid="cit0020" ref-type="bibr">20</xref>]. Przyklenk <italic>et al.</italic> first reported that ischemia in a remote organ could also protect the myocardium against ischemia [<xref rid="cit0021" ref-type="bibr">21</xref>], and later in 2002 Kharbanda <italic>et al.</italic> showed the beneficial effects of RIPC in human subjects [<xref rid="cit0022" ref-type="bibr">22</xref>]. Further RIPC studies have been performed in STEMI, in cardiac surgery and in elective PCI cases [<xref rid="cit0007" ref-type="bibr">7</xref>, <xref rid="cit0008" ref-type="bibr">8</xref>, <xref rid="cit0023" ref-type="bibr">23</xref>&#x02013;<xref rid="cit0026" ref-type="bibr">26</xref>].</p><p>The exact mechanism underlying the protective effect of RIPC on reperfusion injury is not fully understood yet. Although RIPC has promising effects, there are limited data about its effects in planned PCI. Different protocols, to test the possible protective effects of RIPC, were chosen in the previous studies [<xref rid="cit0007" ref-type="bibr">7</xref>, <xref rid="cit0012" ref-type="bibr">12</xref>, <xref rid="cit0025" ref-type="bibr">25</xref>&#x02013;<xref rid="cit0030" ref-type="bibr">30</xref>]. The study by Iliodromitis <italic>et al</italic>. was the first to investigate the effect of RIPC in elective PCI [<xref rid="cit0025" ref-type="bibr">25</xref>]. In that study, 41 patients (20 in the RIPC group and 21 controls) were enrolled, and 3 cycles of 5-minute ischemia were administered to bilateral arms; as a result no cardioprotection was achieved. Moreover, troponin release was exacerbated in the RIPC group. Hoole <italic>et al.</italic> demonstrated that 3 cycles of 5-minute RIPC administered before planned PCI diminished PCI-related myocardial injury, but did not demonstrate an effect on the prevalence of type 4a MI [<xref rid="cit0007" ref-type="bibr">7</xref>]. In the study of Ahmed <italic>et al.</italic>, although there was less procedure-related MI in the preconditioning group, the difference did not reach statistical significance; but the authors also demonstrated attenuated troponin release [<xref rid="cit0027" ref-type="bibr">27</xref>]. In contrast to these 2 studies, Luo <italic>et al.</italic> were able to achieve 15% fewer type 4a MIs in the RIPC group (39% vs. 54%, <italic>p</italic> = 0.029) [<xref rid="cit0026" ref-type="bibr">26</xref>]. Prasad <italic>et al.</italic> [<xref rid="cit0028" ref-type="bibr">28</xref>] used a different protocol and delivered 3 cycles of 3-minute ischemia/reperfusion immediately before PCI, but they were not able to show cardioprotection. Unlike the studies of classical preconditioning, Liu <italic>et al.</italic> demonstrated that late RIPC also had beneficial effects on patients undergoing elective PCI [<xref rid="cit0029" ref-type="bibr">29</xref>]. Although there is heterogeneity in RIPC protocols, meta-analyses of the major RIPC studies in elective PCI indicated that ischemic preconditioning had beneficial effects on post-PCI myocardial injury [<xref rid="cit0031" ref-type="bibr">31</xref>&#x02013;<xref rid="cit0033" ref-type="bibr">33</xref>].</p><p>The RIPC is a simple, cheap and practical technique, but the optimal protocol to achieve the most effective cardioprotection has not yet been demonstrated. There are controversies about the number of cycles, ischemia duration and the limbs used for ischemia. Different protocols have been investigated to minimize the delay of intervention and to improve practicality because 3 cycles of 5-minute RIPC are rather time-consuming and ad-hoc PCI is more commonly performed. In a study by Ghaemian <italic>et al.</italic> 2 cycles of 5-minute ischemia/reperfusion were administered to the lower limb, which revealed a 27.5% reduction in PCI-related myonecrosis [<xref rid="cit0034" ref-type="bibr">34</xref>]. Prasad <italic>et al</italic>. [<xref rid="cit0028" ref-type="bibr">28</xref>] induced 3 cycles of 3-minute RIPC, to shorten the duration of preconditioning, but, consistent with the study of Iliodromitis <italic>et al.</italic> [<xref rid="cit0025" ref-type="bibr">25</xref>], they failed to achieve cardioprotection. One possible reasons for this negative effect was attributed to the shorter duration of ischemia, which implies that 3 min of cuff inflation might not generate sufficient preconditioning.</p><p>In the present study, we performed a single episode of 5-minute ischemia. The number of cycles has been investigated in various studies, and the results were conflicting. In their study of ischemic preconditioning, Li <italic>et al.</italic> stated that preconditioning was an all-or-nothing phenomenon and demonstrated that cardioprotection could be achieved with one cycle of ischemia [<xref rid="cit0009" ref-type="bibr">9</xref>]. In an animal study by Lu <italic>et al.</italic> one cycle of preconditioning did not provide protection, but 3 cycles of ischemia did [<xref rid="cit0035" ref-type="bibr">35</xref>]. Further studies also showed that supplementary cycles could achieve more protection [<xref rid="cit0010" ref-type="bibr">10</xref>, <xref rid="cit0036" ref-type="bibr">36</xref>]. A recently published animal study compared the effects of the number of cycles of RIPC, duration of ischemia, and one or two hind-limb ischemia on ischemia/reperfusion injury [<xref rid="cit0037" ref-type="bibr">37</xref>]. Two, 4, 6 and 8 cycles of ischemia (each lasting 5 min) preceding reperfusion were compared; 2 cycles of RIPC were found ineffective. The authors concluded that the number of cycles and duration of ischemia were the major determinants of efficient preconditioning. Zografos <italic>et al.</italic> were the first to assess the effect of one cycle of RIPC on elective PCI [<xref rid="cit0012" ref-type="bibr">12</xref>]. Unlike our study, they were able to demonstrate significant reduction in the prevalence of type 4a MI (42.6% vs. 19.1%, <italic>p</italic> = 0.014) and in &#x00394;cTn-I (0.04 &#x003bc;g/l vs. 0.19 &#x003bc;g/l, <italic>p</italic> &#x0003c; 0.001). The most remarkable difference of the Zografos <italic>et al.</italic> study compared with the present study is the higher prevalence of type 4a MI (42.6% vs. 21.6%), which can be explained by the higher rate of complications and higher APPROACH score. With the exception that the percentage of patients with diabetes was lower in the study of Zografos <italic>et al.</italic>, the sample size and study population were similar in both studies (21% vs. 31%). The presence of DM could attenuate the protective effects of RIPC [<xref rid="cit0030" ref-type="bibr">30</xref>]. The diabetic group in our study constituted about one third of the study population, without a significant difference between groups. In the Hoole <italic>et al.</italic> and Zografos <italic>et al.</italic> studies the percentage of diabetic patients was about 20%, whereas about 30% of the Ahmed <italic>et al.</italic> and Luo <italic>et al.</italic> studies were diabetic; all were able to achieve positive results with RIPC. As with the previous studies, the present study was also underpowered to investigate the effect of these factors on RIPC.</p><p>The time between the cuff deflation and stent implantation can also be argued as a cause for the discrepancies between the previous studies with 3 cycles of ischemia. However, classical conditioning as we applied is described as preconditioning within 3 h of the ischemic event, and its effect starts immediately and vanishes in about 2&#x02013;3 h [<xref rid="cit0038" ref-type="bibr">38</xref>]. We delivered 5 min of RIPC just before the PCI. The mean cuff deflation to stent implantation time was 432.9 &#x000b1;221.1 s. Zografos <italic>et al.</italic> achieved positive results with a shorter time between cuff deflation and stent implantation.</p><p>One can argue that the control group might also gain benefit from pre- or post-conditioning due to predilatations or postdilatations during PCI. With this study we tried to show the effect of RIPC in real-life clinical practice. The comparison of procedural data (balloon dilatations, duration and number) between the two groups were found similar, so this could not have a significant effect.</p><sec id="sec5.1"><title>Limitations of the study</title><p>One of the major limitations of our study is the small sample size. The results might be different with a larger sample size, and the difference between the groups might be more significant. The other major limitation is that we used cTn-I to detect myocardial injury. Although guidelines recommended cTn-I for the detection of type 4a MI, it may be over-diagnostic and not clinically important. Troponin elevation after PCI occurs between 12 and 24 h. As such serial cTn-I measurements would be more sensitive in detecting the magnitude of myocardial injury. By taking a single blood sample at the 16<sup>th</sup> h of the intervention, we might have missed the maximum concentration. Long-term follow-up and magnetic resonance imaging could have given us more objective data about post-PCI myocardial injury and its clinical relevance.</p></sec></sec><sec sec-type="conclusions" id="sec6"><title>Conclusions</title><p>Remote ischemic preconditioning is a promising technique for reducing PCI-related myocardial injury. Due to the lack of homogeneity of the previous studies, the optimum protocol has not yet been standardized. Although we were able to demonstrate less cTn-I elevation with one cycle of RIPC, we could not show a statistically significant reduction, indicating that one cycle of RIPC might not generate adequate preconditioning. Further randomized, prospective, multi-center, larger scale studies with a long follow-up are needed to determine the most effective RIPC model.</p></sec></body><back><sec sec-type="COI-statement"><title>Conflict of interest</title><p>The authors declare no conflict of interest.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babu</surname><given-names>GG</given-names></name><name><surname>Walker</surname><given-names>JM</given-names></name><name><surname>Yellon</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><fpage>23</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">21037252</pub-id></element-citation></ref><ref id="cit0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>J</given-names></name></person-group><article-title>Peri-procedural myocardial injury: 2005 update</article-title><source>Eur Heart J</source><year>2005</year><volume>26</volume><fpage>2493</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">16176941</pub-id></element-citation></ref><ref id="cit0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvanayagam</surname><given-names>JB</given-names></name><name><surname>Porto</surname><given-names>I</given-names></name><name><surname>Channon</surname><given-names>K</given-names></name><etal/></person-group><article-title>Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging</article-title><source>Circulation</source><year>2005</year><volume>111</volume><fpage>1027</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15723982</pub-id></element-citation></ref><ref id="cit0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liou</surname><given-names>K</given-names></name><name><surname>Jepson</surname><given-names>N</given-names></name><name><surname>Kellar</surname><given-names>P</given-names></name><etal/></person-group><article-title>Prognostic significance of peri-procedural myocardial infarction in the era of high sensitivity troponin: a validation of the Joint ACCF/AHA/ESC/WHF Universal Definition of Type 4a Myocardial Infarction with High Sensitivity Troponin T</article-title><source>Heart Lung Circ</source><year>2015</year><volume>24</volume><fpage>673</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">25697382</pub-id></element-citation></ref><ref id="cit0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heusch</surname><given-names>G</given-names></name><name><surname>Kleinbongard</surname><given-names>P</given-names></name><name><surname>Bose</surname><given-names>D</given-names></name><etal/></person-group><article-title>Coronary microembolization: from bedside to bench and back to bedside</article-title><source>Circulation</source><year>2009</year><volume>120</volume><fpage>1822</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">19884481</pub-id></element-citation></ref><ref id="cit0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heusch</surname><given-names>G</given-names></name><name><surname>Botker</surname><given-names>HE</given-names></name><name><surname>Przyklenk</surname><given-names>K</given-names></name><etal/></person-group><article-title>Remote ischemic conditioning</article-title><source>J Am Coll Cardiol</source><year>2015</year><volume>65</volume><fpage>177</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">25593060</pub-id></element-citation></ref><ref id="cit0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoole</surname><given-names>SP</given-names></name><name><surname>Heck</surname><given-names>PM</given-names></name><name><surname>Sharples</surname><given-names>L</given-names></name><etal/></person-group><article-title>Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial</article-title><source>Circulation</source><year>2009</year><volume>119</volume><fpage>820</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19188504</pub-id></element-citation></ref><ref id="cit0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>WR</given-names></name><name><surname>Brown</surname><given-names>AJ</given-names></name><name><surname>Watson</surname><given-names>W</given-names></name><etal/></person-group><article-title>Remote ischemic preconditioning improves outcome at 6 years after elective percutaneous coronary intervention: the CRISP stent trial long-term follow-up</article-title><source>Circ Cardiovasc Interv</source><year>2013</year><volume>6</volume><fpage>246</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">23696599</pub-id></element-citation></ref><ref id="cit0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>GC</given-names></name><name><surname>Vasquez</surname><given-names>JA</given-names></name><name><surname>Gallagher</surname><given-names>KP</given-names></name><etal/></person-group><article-title>Myocardial protection with preconditioning</article-title><source>Circulation</source><year>1990</year><volume>82</volume><fpage>609</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">2372907</pub-id></element-citation></ref><ref id="cit0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goto</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>XM</given-names></name><etal/></person-group><article-title>Role of bradykinin in protection of ischemic preconditioning in rabbit hearts</article-title><source>Circ Res</source><year>1995</year><volume>77</volume><fpage>611</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">7641331</pub-id></element-citation></ref><ref id="cit0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>R</given-names></name><name><surname>Post</surname><given-names>H</given-names></name><name><surname>Vahlhaus</surname><given-names>C</given-names></name><etal/></person-group><article-title>Ischemic preconditioning in pigs: a graded phenomenon: its relation to adenosine and bradykinin</article-title><source>Circulation</source><year>1998</year><volume>98</volume><fpage>1022</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9737523</pub-id></element-citation></ref><ref id="cit0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zografos</surname><given-names>TA</given-names></name><name><surname>Katritsis</surname><given-names>GD</given-names></name><name><surname>Tsiafoutis</surname><given-names>I</given-names></name><etal/></person-group><article-title>Effect of one-cycle remote ischemic preconditioning to reduce myocardial injury during percutaneous coronary intervention</article-title><source>Am J Cardiol</source><year>2014</year><volume>113</volume><fpage>2013</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">24793669</pub-id></element-citation></ref><ref id="cit0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>TJ</given-names></name><name><surname>Faxon</surname><given-names>DP</given-names></name><name><surname>Gunnar</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty)</article-title><source>Circulation</source><year>1988</year><volume>78</volume><fpage>486</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">2969312</pub-id></element-citation></ref><ref id="cit0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganz</surname><given-names>W</given-names></name></person-group><article-title>The thrombolysis in myocardial infarction (TIMI) trial</article-title><source>N Engl J Med</source><year>1985</year><volume>313</volume><fpage>1018</fpage></element-citation></ref><ref id="cit0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>MM</given-names></name><name><surname>Faris</surname><given-names>PD</given-names></name><name><surname>Ghali</surname><given-names>WA</given-names></name><etal/></person-group><article-title>Validation of three myocardial jeopardy scores in a population-based cardiac catheterization cohort</article-title><source>Am Heart J</source><year>2001</year><volume>142</volume><fpage>254</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">11479464</pub-id></element-citation></ref><ref id="cit0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buturak</surname><given-names>A</given-names></name><name><surname>Degirmencioglu</surname><given-names>A</given-names></name><name><surname>Surgit</surname><given-names>O</given-names></name><etal/></person-group><article-title>Rise of serum troponin levels following uncomplicated elective percutaneous coronary interventions in patients without clinical and procedural signs suggestive of myocardial necrosis</article-title><source>Adv Interv Cardiol</source><year>2016</year><volume>12</volume><fpage>41</fpage><lpage>8</lpage></element-citation></ref><ref id="cit0017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>DN</given-names></name><name><surname>Kim</surname><given-names>L</given-names></name><name><surname>Rene</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Prognostic value of cardiac troponin-I or troponin-T elevation following nonemergent percutaneous coronary intervention: a meta-analysis</article-title><source>Catheter Cardiovasc Interv</source><year>2011</year><volume>77</volume><fpage>1020</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">21574239</pub-id></element-citation></ref><ref id="cit0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moussa</surname><given-names>ID</given-names></name><name><surname>Klein</surname><given-names>LW</given-names></name><name><surname>Shah</surname><given-names>B</given-names></name><etal/></person-group><article-title>Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI)</article-title><source>J Am Coll Cardiol</source><year>2013</year><volume>62</volume><fpage>1563</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">24135581</pub-id></element-citation></ref><ref id="cit0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thygesen</surname><given-names>K</given-names></name><name><surname>Alpert</surname><given-names>JS</given-names></name><name><surname>Jaffe</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Third universal definition of myocardial infarction</article-title><source>Eur Heart J</source><year>2012</year><volume>33</volume><fpage>2551</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">22922414</pub-id></element-citation></ref><ref id="cit0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murry</surname><given-names>CE</given-names></name><name><surname>Jennings</surname><given-names>RB</given-names></name><name><surname>Reimer</surname><given-names>KA</given-names></name></person-group><article-title>Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium</article-title><source>Circulation</source><year>1986</year><volume>74</volume><fpage>1124</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">3769170</pub-id></element-citation></ref><ref id="cit0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Przyklenk</surname><given-names>K</given-names></name><name><surname>Bauer</surname><given-names>B</given-names></name><name><surname>Ovize</surname><given-names>M</given-names></name><etal/></person-group><article-title>Regional ischemic &#x02018;preconditioning&#x02019; protects remote virgin myocardium from subsequent sustained coronary occlusion</article-title><source>Circulation</source><year>1993</year><volume>87</volume><fpage>893</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7680290</pub-id></element-citation></ref><ref id="cit0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kharbanda</surname><given-names>RK</given-names></name><name><surname>Mortensen</surname><given-names>UM</given-names></name><name><surname>White</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Transient limb ischemia induces remote ischemic preconditioning in vivo</article-title><source>Circulation</source><year>2002</year><volume>106</volume><fpage>2881</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">12460865</pub-id></element-citation></ref><ref id="cit0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausenloy</surname><given-names>DJ</given-names></name><name><surname>Candilio</surname><given-names>L</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><etal/></person-group><article-title>Remote ischemic preconditioning and outcomes of cardiac surgery</article-title><source>N Engl J Med</source><year>2015</year><volume>373</volume><fpage>1408</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">26436207</pub-id></element-citation></ref><ref id="cit0024"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>AM</given-names></name><name><surname>Ali</surname><given-names>GS</given-names></name><name><surname>Tariq</surname><given-names>W</given-names></name></person-group><article-title>Remote ischemic preconditioning is a safe adjuvant technique to myocardial protection but adds no clinical benefit after on-pump coronary artery bypass grafting</article-title><source>Heart Surg Forum</source><year>2014</year><volume>17</volume><fpage>E220</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">25179977</pub-id></element-citation></ref><ref id="cit0025"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iliodromitis</surname><given-names>EK</given-names></name><name><surname>Kyrzopoulos</surname><given-names>S</given-names></name><name><surname>Paraskevaidis</surname><given-names>IA</given-names></name><etal/></person-group><article-title>Increased C reactive protein and cardiac enzyme levels after coronary stent implantation. Is there protection by remote ischaemic preconditioning?</article-title><source>Heart</source><year>2006</year><volume>92</volume><fpage>1821</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16855045</pub-id></element-citation></ref><ref id="cit0026"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>SJ</given-names></name><name><surname>Zhou</surname><given-names>YJ</given-names></name><name><surname>Shi</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Remote ischemic preconditioning reduces myocardial injury in patients undergoing coronary stent implantation</article-title><source>Can J Cardiol</source><year>2013</year><volume>29</volume><fpage>1084</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23414904</pub-id></element-citation></ref><ref id="cit0027"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>RM</given-names></name><name><surname>Mohamed el</surname><given-names>HA</given-names></name><name><surname>Ashraf</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of remote ischemic preconditioning on serum troponin T level following elective percutaneous coronary intervention</article-title><source>Catheter Cardiovasc Interv</source><year>2013</year><volume>82</volume><fpage>E647</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">23404916</pub-id></element-citation></ref><ref id="cit0028"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>A</given-names></name><name><surname>Gossl</surname><given-names>M</given-names></name><name><surname>Hoyt</surname><given-names>J</given-names></name><etal/></person-group><article-title>Remote ischemic preconditioning immediately before percutaneous coronary intervention does not impact myocardial necrosis, inflammatory response, and circulating endothelial progenitor cell counts: a single center randomized sham controlled trial</article-title><source>Catheter Cardiovasc Interv</source><year>2013</year><volume>81</volume><fpage>930</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">22517646</pub-id></element-citation></ref><ref id="cit0029"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>YL</given-names></name><name><surname>Hua</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Late remote ischemic preconditioning provides benefit to patients undergoing elective percutaneous coronary intervention</article-title><source>Cell Biochem Biophys</source><year>2014</year><volume>70</volume><fpage>437</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">25015066</pub-id></element-citation></ref><ref id="cit0030"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of remote ischemic preconditioning in the elderly patients with coronary artery disease with diabetes mellitus undergoing elective drug-eluting stent implantation</article-title><source>Angiology</source><year>2014</year><volume>65</volume><fpage>660</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">24163121</pub-id></element-citation></ref><ref id="cit0031"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Ascenzo</surname><given-names>F</given-names></name><name><surname>Moretti</surname><given-names>C</given-names></name><name><surname>Omede</surname><given-names>P</given-names></name><etal/></person-group><article-title>Cardiac remote ischaemic preconditioning reduces periprocedural myocardial infarction for patients undergoing percutaneous coronary interventions: a meta-analysis of randomised clinical trials</article-title><source>EuroIntervention</source><year>2014</year><volume>9</volume><fpage>1463</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">24755386</pub-id></element-citation></ref><ref id="cit0032"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zografos</surname><given-names>TA</given-names></name><name><surname>Katritsis</surname><given-names>GD</given-names></name><name><surname>Katritsis</surname><given-names>DG</given-names></name></person-group><article-title>Remote ischemic preconditioning reduces peri-procedural myocardial injury in elective percutaneous coronary intervention: a meta-analysis</article-title><source>Int J Cardiol</source><year>2014</year><volume>173</volume><fpage>530</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">24681008</pub-id></element-citation></ref><ref id="cit0033"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><etal/></person-group><article-title>Remote ischaemic conditioning in percutaneous coronary intervention: a meta-analysis of randomised trials</article-title><source>Postep Kardiol Interw</source><year>2014</year><volume>10</volume><fpage>274</fpage><lpage>82</lpage></element-citation></ref><ref id="cit0034"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghaemian</surname><given-names>A</given-names></name><name><surname>Nouraei</surname><given-names>SM</given-names></name><name><surname>Abdollahian</surname><given-names>F</given-names></name><etal/></person-group><article-title>Remote ischemic preconditioning in percutaneous coronary revascularization: a double-blind randomized controlled clinical trial</article-title><source>Asian Cardiovasc Thorac Ann</source><year>2012</year><volume>20</volume><fpage>548</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">23087298</pub-id></element-citation></ref><ref id="cit0035"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>CS</given-names></name><name><surname>Yu</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Morphine reduces the threshold of remote ischemic preconditioning against myocardial ischemia and reperfusion injury in rats: the role of opioid receptors</article-title><source>J Cardiothorac Vasc Anesth</source><year>2012</year><volume>26</volume><fpage>403</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">21982329</pub-id></element-citation></ref><ref id="cit0036"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandhu</surname><given-names>R</given-names></name><name><surname>Diaz</surname><given-names>RJ</given-names></name><name><surname>Mao</surname><given-names>GD</given-names></name><etal/></person-group><article-title>Ischemic preconditioning: differences in protection and susceptibility to blockade with single-cycle versus multicycle transient ischemia</article-title><source>Circulation</source><year>1997</year><volume>96</volume><fpage>984</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">9264510</pub-id></element-citation></ref><ref id="cit0037"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnsen</surname><given-names>J</given-names></name><name><surname>Pryds</surname><given-names>K</given-names></name><name><surname>Salman</surname><given-names>R</given-names></name><etal/></person-group><article-title>The remote ischemic preconditioning algorithm: effect of number of cycles, cycle duration and effector organ mass on efficacy of protection</article-title><source>Basic Res Cardiol</source><year>2016</year><volume>111</volume><fpage>10</fpage><pub-id pub-id-type="pmid">26768477</pub-id></element-citation></ref><ref id="cit0038"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hausenloy</surname><given-names>DJ</given-names></name><name><surname>Yellon</surname><given-names>DM</given-names></name></person-group><article-title>Ischaemic conditioning and reperfusion injury</article-title><source>Nat Rev Cardiol</source><year>2016</year><volume>13</volume><fpage>193</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">26843289</pub-id></element-citation></ref></ref-list></back></article>